{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**Reviewer question:** Additionally, the authors mention that “consensus ranks with most trustworthy explanations” (llm_reranking.py). How was trustworthiness determined? Did human reviewers assess and select the most reliable responses from the three outputs, or was an automated method used? Clarifying this process would strengthen the validity of the feature selection approach."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Results directory: /Users/mduranfrigola/Documents/GitHub/pharmacogx-embeddings/results\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import pandas as pd\n",
    "import json\n",
    "import collections\n",
    "\n",
    "results_dir = os.path.abspath(\"../../results\")\n",
    "print(f\"Results directory: {results_dir}\")\n",
    "\n",
    "data = {}\n",
    "responses_dir = os.path.join(results_dir, \"results_pairs\", \"reranking\", \"responses\")\n",
    "for round in [0, 1, 2]:\n",
    "    round_dir = os.path.join(responses_dir, f\"round_{round}\")\n",
    "    for file in os.listdir(os.path.join(round_dir, \"json\")):\n",
    "        if file.endswith(\".json\"):\n",
    "            drug_name = file.split(\".json\")[0]\n",
    "            with open(os.path.join(round_dir, \"json\", file), \"r\") as f:\n",
    "                ranks = json.load(f)\n",
    "                key = (drug_name, round)\n",
    "                data[key] = ranks\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "table = collections.defaultdict(list)\n",
    "for k,v in data.items():\n",
    "    drug_name, round = k\n",
    "    for rank in v:\n",
    "        gene = rank[\"gene\"]\n",
    "        r = rank[\"rank\"]\n",
    "        explanation = rank[\"explanation\"]\n",
    "        table[(drug_name, gene, r)] += [(round, explanation)]\n",
    "\n",
    "R = []\n",
    "for k,v in table.items():\n",
    "    R += [[k[0], k[1], k[2]] + [x[1] for x in v]]\n",
    "\n",
    "df = pd.DataFrame(R, columns=[\"drug\", \"gene\", \"rank\", \"explanation_0\", \"explanation_1\", \"explanation_2\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv(\"assets/reranking_explanations.csv\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug</th>\n",
       "      <th>gene</th>\n",
       "      <th>rank</th>\n",
       "      <th>explanation_0</th>\n",
       "      <th>explanation_1</th>\n",
       "      <th>explanation_2</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Rifapentine</td>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>1</td>\n",
       "      <td>CYP3A4 significantly alters the metabolism and...</td>\n",
       "      <td>CYP3A4 is instrumental in drug metabolism part...</td>\n",
       "      <td>CYP3A4 metabolizes a significant proportion of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Rifapentine</td>\n",
       "      <td>CYP2C9</td>\n",
       "      <td>2</td>\n",
       "      <td>Certain alleles of CYP2C9 may decrease enzyme ...</td>\n",
       "      <td>The gene CYP2C9 plays a crucial metabolic role...</td>\n",
       "      <td>CYP2C9 is another essential enzyme influencing...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Rifapentine</td>\n",
       "      <td>SLCO1B1</td>\n",
       "      <td>3</td>\n",
       "      <td>This gene codes for a hepatic uptake transport...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Rifapentine</td>\n",
       "      <td>NR1I2</td>\n",
       "      <td>4</td>\n",
       "      <td>NR1I2 carries implications for Rifapentine's p...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Rifapentine</td>\n",
       "      <td>NAT2</td>\n",
       "      <td>5</td>\n",
       "      <td>Variations in NAT2 often impact drug response ...</td>\n",
       "      <td>NAT2 is involved in the process of N-acetylati...</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>731</th>\n",
       "      <td>Delamanid</td>\n",
       "      <td>CYP3A5</td>\n",
       "      <td>6</td>\n",
       "      <td>CYP3A5 is involved in metabolism of several dr...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>732</th>\n",
       "      <td>Delamanid</td>\n",
       "      <td>CYP2C19</td>\n",
       "      <td>7</td>\n",
       "      <td>CYP2C19 significantly influences the metabolis...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>733</th>\n",
       "      <td>Delamanid</td>\n",
       "      <td>CYP2D7</td>\n",
       "      <td>8</td>\n",
       "      <td>Although CYP2D7 is a pseudogene and does not c...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>734</th>\n",
       "      <td>Delamanid</td>\n",
       "      <td>CYP2B6</td>\n",
       "      <td>9</td>\n",
       "      <td>CYP2B6 is known to metabolize several importan...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>735</th>\n",
       "      <td>Delamanid</td>\n",
       "      <td>CYP2C9</td>\n",
       "      <td>10</td>\n",
       "      <td>CYP2C9 is involved in the metabolic breakdown ...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>736 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            drug     gene  rank  \\\n",
       "0    Rifapentine   CYP3A4     1   \n",
       "1    Rifapentine   CYP2C9     2   \n",
       "2    Rifapentine  SLCO1B1     3   \n",
       "3    Rifapentine    NR1I2     4   \n",
       "4    Rifapentine     NAT2     5   \n",
       "..           ...      ...   ...   \n",
       "731    Delamanid   CYP3A5     6   \n",
       "732    Delamanid  CYP2C19     7   \n",
       "733    Delamanid   CYP2D7     8   \n",
       "734    Delamanid   CYP2B6     9   \n",
       "735    Delamanid   CYP2C9    10   \n",
       "\n",
       "                                         explanation_0  \\\n",
       "0    CYP3A4 significantly alters the metabolism and...   \n",
       "1    Certain alleles of CYP2C9 may decrease enzyme ...   \n",
       "2    This gene codes for a hepatic uptake transport...   \n",
       "3    NR1I2 carries implications for Rifapentine's p...   \n",
       "4    Variations in NAT2 often impact drug response ...   \n",
       "..                                                 ...   \n",
       "731  CYP3A5 is involved in metabolism of several dr...   \n",
       "732  CYP2C19 significantly influences the metabolis...   \n",
       "733  Although CYP2D7 is a pseudogene and does not c...   \n",
       "734  CYP2B6 is known to metabolize several importan...   \n",
       "735  CYP2C9 is involved in the metabolic breakdown ...   \n",
       "\n",
       "                                         explanation_1  \\\n",
       "0    CYP3A4 is instrumental in drug metabolism part...   \n",
       "1    The gene CYP2C9 plays a crucial metabolic role...   \n",
       "2                                                 None   \n",
       "3                                                 None   \n",
       "4    NAT2 is involved in the process of N-acetylati...   \n",
       "..                                                 ...   \n",
       "731                                               None   \n",
       "732                                               None   \n",
       "733                                               None   \n",
       "734                                               None   \n",
       "735                                               None   \n",
       "\n",
       "                                         explanation_2  \n",
       "0    CYP3A4 metabolizes a significant proportion of...  \n",
       "1    CYP2C9 is another essential enzyme influencing...  \n",
       "2                                                 None  \n",
       "3                                                 None  \n",
       "4                                                 None  \n",
       "..                                                 ...  \n",
       "731                                               None  \n",
       "732                                               None  \n",
       "733                                               None  \n",
       "734                                               None  \n",
       "735                                               None  \n",
       "\n",
       "[736 rows x 6 columns]"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "df[df[\"explanation_2\"].notnull()].to_csv(\"assets/reranking_explanations_filtered.csv\", index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "To evaluate robustness of predictions, we can use embeddings from OpenAI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "from dotenv import load_dotenv\n",
    "import openai\n",
    "load_dotenv(\"../../.env\")\n",
    "\n",
    "openai.api_key = os.getenv(\"OPENAI_API_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "import openai\n",
    "import numpy as np\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "def get_embedding(text: str, model: str = \"text-embedding-3-small\") -> np.ndarray:\n",
    "    response = openai.embeddings.create(\n",
    "        input=[text],\n",
    "        model=model\n",
    "    )\n",
    "    return np.array(response.data[0].embedding)\n",
    "\n",
    "def paragraph_similarity(p1: str, p2: str, verbose: bool = True) -> float:\n",
    "    emb1 = get_embedding(p1)\n",
    "    emb2 = get_embedding(p2)\n",
    "    similarity = cosine_similarity([emb1], [emb2])[0][0]\n",
    "    if verbose:\n",
    "        print(f\"Cosine similarity: {similarity:.4f}\")\n",
    "        if similarity > 0.85:\n",
    "            print(\"→ Very similar content.\")\n",
    "        elif similarity > 0.6:\n",
    "            print(\"→ Related but not identical.\")\n",
    "        else:\n",
    "            print(\"→ Possibly unrelated.\")\n",
    "    return float(similarity)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Comparing explanations for drug Terizidone, gene CYP2C9:\n",
      "Explanation 0: CYP2C9 metabolizes various drugs, where genetic variants significantly affect those drugs' therapeutic effectiveness and adverse effects. Given the direct link between terizidone and the cytochromes P450 family indicated in the auxiliary materials, CYP2C9 stands out as a potential player in terizidone's pharmacogenetic interactions, possibly influencing metabolism, efficacy, and side effects.\n",
      "Explanation 1: CYP2C9 alterations influence the pharmacokinetics of various drugs by playing a key role in their metabolism. Variations in this gene, hence, dictate the personalized methodologies used for drug dosage adjustments. Given that CYP2C9 likely influences the metabolism of Terizidone, its variants could impact the drug's overall effectiveness and risk of side effects.\n",
      "Cosine similarity: 0.9160\n",
      "→ Very similar content.\n",
      "Similarity: 0.9160\n",
      "\n",
      "Comparing explanations for drug Piperaquine, gene CYP2C19:\n",
      "Explanation 0: CYP2C19 mediates the metabolism of several medications, significantly influencing their pharmacokinetics. The enzyme's polymorphisms can lead to different metabolic rates, affecting the plasma levels of Piperaquine. By altering the drug's clearance and bioavailability, these variations may impact therapeutic outcomes, leading to treatment failures or toxicity. Therefore, CYP2C19 is an important candidate in the genetic modulation of Piperaquine's pharmacogenetic interactions.\n",
      "Explanation 1: The enzyme CYP2C19 hugely impacts the metabolism and effectiveness of numerous drugs, asserting an influence on their therapeutic efficacy, safety, and dosage requirements. Specifically, for Piperaquine, genetic polymorphisms in CYP2C19 can alter metabolic rates, influencing plasma levels of the drug, and potentially leading to therapeutic failures or toxicity due to changes in drug clearance and bioavailability. Therefore, CYP2C19 carries a high likelihood for a pharmacogenetic relationship with Piperaquine.\n",
      "Cosine similarity: 0.9533\n",
      "→ Very similar content.\n",
      "Similarity: 0.9533\n",
      "\n",
      "Comparing explanations for drug lumefantrine, gene CYP3A4:\n",
      "Explanation 0: CYP3A4 is a key enzyme involved in the metabolism of a wide range of drugs. Its specific relevance to lumefantrine metabolism has been documented and can directly impact the drug’s efficacy and safety profiles. Genetic variations in CYP3A4 have been shown to alter lumefantrine levels in patients with malaria, necessitating a personalized approach to treatment. Furthermore, CYP3A4's broad role in drug metabolism suggests that it could influence responses to other drugs used in combination with lumefantrine or as part of a broader treatment protocol.\n",
      "Explanation 1: CYP3A4 is a paramount actor in the metabolism of lumefantrine. Largely expressed in the liver and intestine, it metabolizes many drugs including tacrolimus and statins. This gene’s pharmacological interactions are critical for delivering personalized malaria treatment as its activity may alter drug levels, thus changing the drug's effectiveness and safety profile. Therefore, this gene holds a high chance of being intimately associated with this particular drug's pharmacogenomic landscape.\n",
      "Cosine similarity: 0.8863\n",
      "→ Very similar content.\n",
      "Similarity: 0.8863\n",
      "\n",
      "Comparing explanations for drug Dihydroartemisinin, gene CYP2C19:\n",
      "Explanation 0: CYP2C19 is involved in the metabolism of a diverse range of drugs like clozapine, proton pump inhibitors, antidepressants, antiepileptics, and antifungal drugs. Changes in CYP2C19 perfectly align with variations in drug activation and metabolic rates, thereby causing differences in pharmacological outcomes. Consequently, these pharmacokinetic changes may call for adjustments in dosing to optimize treatment efficacy and avoid adverse effects.\n",
      "Explanation 1: CYP2C19 is responsible for the metabolism of a variety of popular drugs such as clopidogrel, antidepressants, antiepileptics, and antifungals. Variations in the CYP2C19 gene can cause altered drug activation and metabolism, significantly affecting pharmacological outcomes and necessitating genotype-guided dosing. Considering the crucial role of CYP2C19 in managing different bioactive compounds and its involvement in Artenimol metabolism, it is reasonable to anticipate a pharmacogenetic relationship with Dihydroartemisinin.\n",
      "Cosine similarity: 0.7399\n",
      "→ Related but not identical.\n",
      "Similarity: 0.7399\n",
      "\n",
      "Comparing explanations for drug amodiaquine, gene CYP2C19:\n",
      "Explanation 0: While the role of CYP2C19 in the metabolism of amodiaquine is not clear, potential interactions could exist, given CYP2C19's significant contribution to drug metabolism. Genetic variations that alter CYP2C19 activity could in theory affect amodiaquine's pharmacokinetics, particularly in combination therapies involving other CYP2C19-metabolized drugs, possibly impacting drug efficacy or risk of side effects.\n",
      "Explanation 1: CYP2C19 has significant influence on the metabolism of various drugs, but its relationship with amodiaquine is still not fully understood. However, given the broad influence of CYP2C19 on drug activation and metabolism, there's a likelihood that variation in this gene could alter amodiaquine's pharmacokinetics and safety profile.\n",
      "Cosine similarity: 0.9299\n",
      "→ Very similar content.\n",
      "Similarity: 0.9299\n",
      "\n",
      "Comparing explanations for drug primaquine, gene CYP1A2:\n",
      "Explanation 0: CYP1A2, another crucial member of the cytochrome P450 family, has a significant influence on primaquine's pharmacology. Common variants in CYP1A2 have been implicated in alterations in drug metabolism, a crucial determinant of primaquine’s efficacy and safety. Primaquine, along with drugs such as theophylline, caffeine, and clopidogrel, are processed by CYP1A2, where genetic variations can greatly affect therapeutic outcomes. As such, CYP1A2 has a considerable role in the pharmacogenetics of primaquine.\n",
      "Explanation 2: CYP1A2 has also been identified as a key player in the metabolization of primaquine, therefore genetic variability within this gene could significantly affect clinical outcomes.\n",
      "Cosine similarity: 0.8701\n",
      "→ Very similar content.\n",
      "Similarity: 0.8701\n",
      "\n",
      "Comparing explanations for drug Terizidone, gene CYP2B6:\n",
      "Explanation 1: CYP2B6 metabolizes a variety of drugs, and its genetic polymorphisms can significantly influence drug efficacy and safety by modifying pharmacokinetic profiles, affecting drug plasma concentrations, therapeutic effects, and potential adverse reactions. Although terizidone is not mentioned specifically, the versatility of CYP2B6 in drug metabolism anchors its potential role in terizidone's pharmacogenetics, meriting high priority.\n",
      "Explanation 2: CYP2B6 metabolizes several drugs, where genetic polymorphisms present this gene significantly influence the patients' therapeutic success and safety experience due to drastic alterations to the drugs' pharmacokinetic profiles. As such, CYP2B6 polymorphisms likely affect the activity of the enzyme that metabolizes Terizidone, leading to different plasma concentrations, and ultimately, altering the effectiveness and safety of Terizidone therapy.\n",
      "Cosine similarity: 0.9480\n",
      "→ Very similar content.\n",
      "Similarity: 0.9480\n",
      "\n",
      "Comparing explanations for drug ethionamide, gene FMO4:\n",
      "Explanation 0: The noted role of FMO2 in metabolizing ethionamide in the liver suggests a potential interaction with FMO4, a member of the FMO family similarly expressed in the liver. Genetic variations in FMO4 might influence the efficacy and activation of ethionamide. Although FMO4 has not been well-documented in drug interactions compared to FMO2, the chance of shared substrate specificity between these closely related enzymes suggests a possible pharmacogenetic relationship with ethionamide.\n",
      "Explanation 1: Ethionamide is metabolized with variant efficacy due to FMO2 enzymatic activity. Although FMO4's interactions with specific drugs are currently not well-documented, as a flavin-containing monooxygenase, it potentially contributes to the metabolism of drugs by affecting their pharmacokinetics. Considering the similarity in enzyme functions between FMO2 and FMO4, and the impact of FMO2 on ethionamide activation, a pharmacogenetic relationship between FMO4 and ethionamide susceptibility is plausible.\n",
      "Cosine similarity: 0.9218\n",
      "→ Very similar content.\n",
      "Similarity: 0.9218\n",
      "\n",
      "Comparing explanations for drug Piperaquine, gene CYP2C19:\n",
      "Explanation 1: The enzyme CYP2C19 hugely impacts the metabolism and effectiveness of numerous drugs, asserting an influence on their therapeutic efficacy, safety, and dosage requirements. Specifically, for Piperaquine, genetic polymorphisms in CYP2C19 can alter metabolic rates, influencing plasma levels of the drug, and potentially leading to therapeutic failures or toxicity due to changes in drug clearance and bioavailability. Therefore, CYP2C19 carries a high likelihood for a pharmacogenetic relationship with Piperaquine.\n",
      "Explanation 0: CYP2C19 mediates the metabolism of several medications, significantly influencing their pharmacokinetics. The enzyme's polymorphisms can lead to different metabolic rates, affecting the plasma levels of Piperaquine. By altering the drug's clearance and bioavailability, these variations may impact therapeutic outcomes, leading to treatment failures or toxicity. Therefore, CYP2C19 is an important candidate in the genetic modulation of Piperaquine's pharmacogenetic interactions.\n",
      "Cosine similarity: 0.9535\n",
      "→ Very similar content.\n",
      "Similarity: 0.9535\n",
      "\n",
      "Comparing explanations for drug quinine, gene CYP1A2:\n",
      "Explanation 1: CYP1A2 contributes to the metabolism of various drugs, including clozapine, theophylline, caffeine, erlotinib, and deferasirox. Its pivotal role in the hepatic biotransformation reactions denotes its potential to affect the secondary metabolic pathways of quinine and consequently its pharmacokinetics, despite not being a principal enzyme in quinine metabolism. Thus, variations in CYP1A2 could further modulate quinine's effectiveness and safety profiles.\n",
      "Explanation 0: CYP1A2 plays an important role in influencing the metabolism and therefore the efficacy and safety of drugs. While CYP1A2 is a minor metabolizing enzyme for quinine, genetic variability or concurrent medication use that induces or inhibits CYP1A2 could alter quinine metabolism and thus its clinical activity.\n",
      "Cosine similarity: 0.8236\n",
      "→ Related but not identical.\n",
      "Similarity: 0.8236\n",
      "\n",
      "Comparing explanations for drug pyrazinamide, gene NAT2:\n",
      "Explanation 0: NAT2 plays an active role in pyrazinamide metabolism in the liver through acetylation and directly impacts the drug's efficacy and drug-induced lupus risks. As this gene is already associated with pyrazinamide via a known pharmacogenetic relationship, it is key to consider in the context of patient response variability.\n",
      "Explanation 1: NAT2 is known to play a major role in the metabolism of pyrazinamide. The NAT2 gene produces an enzyme which is vital for metabolizing drugs through N-acetylation processes. Variations in NAT2 affect the metabolism of pyrazinamide leading to differences in the drug's plasma levels, exposure duration, and the risk of adverse effects such as increased toxicity. Specifically, genetic variants in NAT2 influencing the enzyme's activity can potentially impact pyrazinamide's pharmacokinetics and toxicity, impacting its efficacy and side effect profile, particularly its known hepatotoxic implications. Thus, NAT2's direct involvement in the metabolism of pyrazinamide establishes it as a significant player in the pharmacogenetics of the drug.\n",
      "Cosine similarity: 0.8970\n",
      "→ Very similar content.\n",
      "Similarity: 0.8970\n",
      "\n",
      "Comparing explanations for drug Capreomycin, gene ABCC2:\n",
      "Explanation 1: The ABCC2 gene encodes the MRP2 protein, an efflux transporter known to play a critical role in the pharmacokinetics of several drugs. Genetic variations in this gene, such as c.1249G>A and c.3972C>T, influence its function, thereby modifying the excretion and plasma concentrations of different drugs. As such, ABCC2 could potentially affect the effectiveness and toxicity of Capreomycin by modulating its transportation, absorption, distribution, and excretion within the body.\n",
      "Explanation 2: ABCC2 gene encodes for the MRP2 protein, which is known to be involved in the transport and excretion of various drugs, and thus directly influences their pharmacokinetics. Variants in ABCC2 affect the excretion and plasma concentrations of certain drugs, impacting their effectiveness and toxicity. Given the broad range of drugs affected by variations in this gene, it is logical to propose a potential pharmacogenetic relationship between ABCC2 and Capreomycin, influencing the drug uptake and excretion of Capreomycin, which, in turn, could affect the efficacy and toxicity of the drug.\n",
      "Cosine similarity: 0.9550\n",
      "→ Very similar content.\n",
      "Similarity: 0.9550\n",
      "\n",
      "Comparing explanations for drug chloroquine, gene ABCB1:\n",
      "Explanation 1: ABCB1 encodes the P-glycoprotein responsible for drug efflux influencing the absorption, distribution, and excretion of the many drugs it interacts with - including chloroquine. Variants of this gene can affect bioavailability, requiring careful monitoring and dosage adjustments to optimize therapeutic outcomes. Its role in affecting the pharmacokinetics of chloroquine makes it a significant contender in the pharmacogenetic landscape.\n",
      "Explanation 0: ABCB1 encodes the transporter protein P-glycoprotein, which impacts pharmacokinetics of multiple drugs by altering absorption, distribution, and excretion. ABCB1 significantly influences the bioavailability and distribution of chloroquine, suggesting that ABCB1 variants could translate into altered distribution and altered response to chloroquine treatment. This highlights the pharmacogenetic relevance of ABCB1-chloroquine interaction.\n",
      "Cosine similarity: 0.9259\n",
      "→ Very similar content.\n",
      "Similarity: 0.9259\n",
      "\n",
      "Comparing explanations for drug Linezolide, gene ABCB1:\n",
      "Explanation 1: ABCB1 gene encodes the drug efflux pump P-glycoprotein, which is involved in the translocation of drugs from the cytoplasm to the extracellular space. ABCB1 has been linked to alterations in pharmacokinetics affecting absorption, distribution, and excretion of many drugs and might also be significant in terms of Linezolid. Linezolid, being a substrate for efflux pumps, could potentially be influenced by ABCB1, affecting its bioavailability, distribution, and elimination.\n",
      "Explanation 0: ABCB1 is the gene coding for P-glycoprotein, an efflux transporter affecting absorption, distribution, and excretion of numerous drugs. Its significant effect on the bioavailability and brain penetration of Linezolide and the documented influence of genotypic variations justifies the second place in this ranking.\n",
      "Cosine similarity: 0.8490\n",
      "→ Related but not identical.\n",
      "Similarity: 0.8490\n",
      "\n",
      "Comparing explanations for drug quinine, gene SLC22A1:\n",
      "Explanation 1: The SLC22A1 gene encodes the organic cation transporter 1 (OCT1), which is known to significantly affect quinine’s distribution and clearance. Genetic variations in SLC22A1 can lead to altered drug absorption, distribution, metabolism, and excretion (ADME) properties, affecting the safety and efficacy of quinine therapy. As such, the potential interaction between quinine and the SLC22A1 gene suggests a potential pharmacogenetic relationship worth further investigation.\n",
      "Explanation 2: The gene SLC22A1 encodes the Organic Cation Transporter 1 (OCT1), which affects the hepatic uptake, and thus the overall disposition, of numerous drugs. OCT1 has an integral role in shaping the bioavailability of drugs such as metformin, tramadol, lamotrigine, ondansetron, and imatinib. In the context of quinine pharmacogenetics, this transporter can potentially influence quinine clearance, modifying the drug's therapeutic efficacy and safety profile.\n",
      "Cosine similarity: 0.8470\n",
      "→ Related but not identical.\n",
      "Similarity: 0.8470\n",
      "\n",
      "Comparing explanations for drug mefloquine, gene CYP3A5:\n",
      "Explanation 1: CYP3A5 has key roles in the metabolism of several drugs, especially those undergoing substantial hepatic metabolism. It affects metabolism and effectiveness of drugs such as immunosuppressants, statins, antifungals, anticoagulants, and opioids. Genetic variants in CYP3A5 impact metabolism rates, thereby affecting dosing because of altered exposure levels. Given their known role in drug metabolism, variations in the CYP3A5 gene could predictably alter pharmacokinetic profiles of mefloquine.\n",
      "Explanation 0: CYP3A5, like CYP3A4, plays a critical role in the metabolism of several drugs, and genetic variants can impact their dosing due to altered metabolism rates. While direct interactions with mefloquine are less established, its role in metabolizing similar drugs suggests a potential pharmacogenetic relevance through shared metabolic pathways.\n",
      "Cosine similarity: 0.9148\n",
      "→ Very similar content.\n",
      "Similarity: 0.9148\n",
      "\n",
      "Comparing explanations for drug Linezolide, gene SLC22A1:\n",
      "Explanation 1: SLC22A1 contributes significantly to drug pharmacokinetics, majorly by affecting their hepatic uptake and distribution. Potential variations in this gene could lead to differential efficacy and safety profiles for Linezolid. Given the significance of SLC22A1 in determining drug levels in the liver and potential implications on hepatotoxicity, its assumed interaction with Linezolid cannot be disregarded.\n",
      "Explanation 0: SLC22A1 gene is notable in regards to pharmacokinetics of Linezolide, especially in terms of altering its hepatic uptake. Its influence on Linezolide's efficacy and safety profile due to variation in its gene activity warrants the 4th rank.\n",
      "Cosine similarity: 0.8454\n",
      "→ Related but not identical.\n",
      "Similarity: 0.8454\n",
      "\n",
      "Comparing explanations for drug Rifapentine, gene CYP2C9:\n",
      "Explanation 0: Certain alleles of CYP2C9 may decrease enzyme activity, leading to increased Rifapentine exposure and potential adverse effects. Patients with these variants may have altered drug metabolism, leading to a higher risk of toxicity and adverse reactions due to increased systemic exposure. Hence, CYP2C9 variations may have a significant influence on the pharmacogenetics of Rifapentine, emphasizing its importance in personalized dosing decisions.\n",
      "Explanation 2: CYP2C9 is another essential enzyme influencing Rifapentine's metabolic pathway. Certain alleles of CYP2C9 can result in reduced enzyme activity, potentially leading to heightened Rifapentine exposure and increased risk of adverse effects, owing to slower drug metabolism. Beyond Rifapentine, a substantial number of other routine medications like warfarin, phenytoin, among others are metabolized by CYP2C9, further emphasizing the gene's role in mediating therapeutic effectiveness and risk of side effects.\n",
      "Cosine similarity: 0.9142\n",
      "→ Very similar content.\n",
      "Similarity: 0.9142\n",
      "\n",
      "Comparing explanations for drug primaquine, gene CYP2D6:\n",
      "Explanation 0: The cytochrome P450 family member CYP2D6 is known to significantly influence the metabolism of primaquine, an antimalarial drug. Primaquine's efficacy and safety are affected by alterations in drug metabolism, which can arise from polymorphisms in the CYP2D6 gene. CYP2D6, widely known to metabolize a broad range of drugs including antidepressants, antipsychotics, opioids, and beta blockers, has significant variations in enzyme activity among individuals, leading to varied therapeutic outcomes. As an essential part of drug metabolism, CYP2D6 is a crucial player in primaquine's pharmacological action, and variations can lead to different primaquine plasma levels, modifying its effectiveness and potential toxicity.\n",
      "Explanation 1: CYP2D6 is crucial in the pharmacokinetics of primaquine, one of the many drugs it metabolizes. Known polymorphisms in this enzyme can significantly affect the metabolism of primaquine, impacting both the drug's efficacy and toxicity. These polymorphisms can lead to diverse therapeutic outcomes: poor metabolizers may experience toxicity due to decreased metabolism and consequent increased primaquine levels, while ultrarapid metabolizers may have diminished drug efficacy due to accelerated metabolism and reduced plasma drug levels. Given the clear pharmacogenetic association and the critical role that CYP2D6 plays in primaquine metabolism, it earns the top spot on this list.\n",
      "Cosine similarity: 0.8992\n",
      "→ Very similar content.\n",
      "Similarity: 0.8992\n",
      "\n",
      "Comparing explanations for drug lumefantrine, gene CYP3A4:\n",
      "Explanation 2: CYP3A4, an enzyme significantly expressed in the liver and small intestine, influences the metabolism and thus effects and toxicity of lumefantrine. Variants in the CYP3A4 gene significantly affect the metabolism of lumefantrine, thereby impacting its efficacy and safety. Genetic interactions with inducers or inhibitors can either amplify or decrease CYP3A4’s activity, necessitating lumefantrine dosage adjustments.\n",
      "Explanation 0: CYP3A4 is a key enzyme involved in the metabolism of a wide range of drugs. Its specific relevance to lumefantrine metabolism has been documented and can directly impact the drug’s efficacy and safety profiles. Genetic variations in CYP3A4 have been shown to alter lumefantrine levels in patients with malaria, necessitating a personalized approach to treatment. Furthermore, CYP3A4's broad role in drug metabolism suggests that it could influence responses to other drugs used in combination with lumefantrine or as part of a broader treatment protocol.\n",
      "Cosine similarity: 0.9033\n",
      "→ Very similar content.\n",
      "Similarity: 0.9033\n",
      "\n",
      "Comparing explanations for drug Pretomanid, gene CYP3A5:\n",
      "Explanation 0: Although its role is not as prominent as CYP3A4 in Pretomanid's metabolism, CYP3A5, due to its similar enzymatic function, could also affect the pharmacokinetics of the drug. Genetic polymorphisms of CYP3A5 resulting in reduced or absent enzyme activity might influence Pretomanid's metabolic pathway, influencing its efficacy and side effect profile.\n",
      "Explanation 2: CYP3A5 influences the metabolism of many drugs, altering their therapeutic outcomes. Given the potential overlap in substrate specificity between CYP3A5 and CYP3A4 (which is involved in Pretomanid metabolism), CYP3A5 could also potentially affect Pretomanid's pharmacokinetics.\n",
      "Cosine similarity: 0.9046\n",
      "→ Very similar content.\n",
      "Similarity: 0.9046\n",
      "\n",
      "Comparing explanations for drug mefloquine, gene CYP2C9:\n",
      "Explanation 0: CYP2C9 gene polymorphisms can influence metabolism of numerous drugs, thereby affecting their therapeutic effectiveness and risk of adverse effects. Drugs such as anticoagulants and antiepileptics require dose customization based on CYP2C9 genetic variants to optimize treatment outcomes and minimize complications. Considering these known pharmacogenetic interactions, the CYP2C9 gene may be plausibly associated with modifications to the pharmacokinetics of mefloquine.\n",
      "Explanation 1: CYP2C9 gene polymorphisms influence the metabolism of various drugs, affecting their therapeutic effectiveness and risk of side effects. Although not directly linked to mefloquine, the drug might still exhibit altered pharmacokinetic profiles and thereby efficacy or safety due to its potential metabolism by CYP2C9, aiding in personalized medicine efforts.\n",
      "Cosine similarity: 0.9313\n",
      "→ Very similar content.\n",
      "Similarity: 0.9313\n",
      "\n",
      "Comparing explanations for drug Capreomycin, gene ABCB1:\n",
      "Explanation 0: ABCB1 encodes P-glycoprotein, a crucial efflux transporter that modulates the pharmacokinetics and efficacy of an array of drugs by regulating their absorption, distribution, and excretion. This consequently affects the bioavailability of these drugs, including Capreomycin. Variations in ABCB1 can lead to variable therapeutic outcomes and can potentially influence the toxicity of drugs due to altered drug exposures and systemic concentrations.\n",
      "Explanation 1: ABCB1 encodes the P-glycoprotein, a crucial player in the pharmacokinetics of numerous medications. It acts as an efflux transporter that modifies the absorption, distribution, and excretion of various drugs. Given its broad scope of function, ABCB1 could plausibly influence the pharmacokinetics of Capreomycin, affecting the drug's bioavailability and penetration in different tissues, potentially leading to variable treatment outcomes.\n",
      "Cosine similarity: 0.9678\n",
      "→ Very similar content.\n",
      "Similarity: 0.9678\n",
      "\n",
      "Comparing explanations for drug ethambutol, gene NAT2:\n",
      "Explanation 1: NAT2 is known to influence the metabolism of ethambutol, with variants tied to 'slow' and 'rapid' acetylator phenotypes leading to significant differences in plasma levels and exposure duration. 'Slow' acetylator alleles correspond to lower enzymatic activity and consequently higher ethambutol exposure, raising the risk of adverse effects like optic neuritis. Thus, NAT2 is of high relevance in determining the pharmacokinetics and potential toxicity of ethambutol.\n",
      "Explanation 0: Ethambutol pharmacogenetics is significantly influenced by NAT2. Given the known association of NAT2 with many drugs that require acetylation for metabolism, its crucial influence on ethambutol’s metabolism is highly probable. Genetic polymorphisms leading to slow NAT2 acetylator status may increase risks for adverse effects of ethambutol, suggesting that the drug's efficacy and safety may vary significantly among individuals of different NAT2 genotypes.\n",
      "Cosine similarity: 0.9007\n",
      "→ Very similar content.\n",
      "Similarity: 0.9007\n",
      "\n",
      "Comparing explanations for drug rifampin, gene GSTM1:\n",
      "Explanation 1: GSTM1 is involved in detoxification pathways and metabolism of a number of drugs, including rifampin. The GSTM1 null genotype leads to decreased enzyme activity, which could impact rifampin's plasma levels, elimination rates, and potential for toxicity. Variations in GSTM1 could thus significantly influence rifampin's efficacy and adverse effects.\n",
      "Explanation 0: GSTM1 has a central role in the metabolism of Rifampin. The presence of a null genotype of GSTM1 leads to a complete loss of enzymatic activity, potentially increasing plasma levels and slowing elimination rates, which could increase drug exposure and toxicity. This suggests that the genetic status of GSTM1 influences both the effectiveness and the potential adverse effects of Rifampin.\n",
      "Cosine similarity: 0.9441\n",
      "→ Very similar content.\n",
      "Similarity: 0.9441\n",
      "\n",
      "Comparing explanations for drug Terizidone, gene ABCC2:\n",
      "Explanation 0: Considering Terizidone's auxiliary information, drugs interacting with this compound potentially rely heavily on metabolism via aldehyde dehydrogenases and transport via ABC transporters like ABCC2 for efficacy and safety. ABCC2, also known as MRP2, affects various drugs' pharmacokinetic profiles. Mutations in this gene can alter drug excretion and plasma concentrations, leading to changes in drug effectiveness and toxicity. Specifically, for Terizidone, interaction with ABCC2 might influence the drug's distribution and excretion, hence possibly affecting its therapeutic outcomes.\n",
      "Explanation 1: ABCC2, a gene that encodes the MRP2 protein, is known to have a substantial impact on the pharmacokinetics and therapeutic outcomes of various drugs by affecting their excretion and plasma concentrations. Variants in ABCC2 can alter these interactions and therefore impact drug effectiveness and toxicity. Given the potential influence of ABC transporter family genes on terizidone as indicated in the auxiliary information, ABCC2 emerges as a crucial candidate. Therefore, it is reasonable to hypothesize that variations in the ABCC2 gene might similarly impact the pharmacokinetics and toxicity of terizidone, affecting its absorption, distribution, metabolism and elimination.\n",
      "Cosine similarity: 0.8704\n",
      "→ Very similar content.\n",
      "Similarity: 0.8704\n",
      "\n",
      "Comparing explanations for drug primaquine, gene G6PD:\n",
      "Explanation 1: G6PD deficiency significantly influences the safety and efficacy of primaquine. Individuals with this deficiency have increased susceptibility to hemolytic anemia when treated with primaquine, due to an inherent vulnerability of their red blood cells to oxidative damage. This is a clear illustration of a pharmacogenetic interaction: the effect of primaquine treatment is significantly influenced by the patient's genetic makeup, specifically, the presence or absence of G6PD deficiency.\n",
      "Explanation 2: Primaquine often causes hemolytic anemia in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to increased vulnerability of red blood cells to oxidative damage. Hence, testing for G6PD deficiency is usually conducted before primaquine treatment.\n",
      "Cosine similarity: 0.8716\n",
      "→ Very similar content.\n",
      "Similarity: 0.8716\n",
      "\n",
      "Comparing explanations for drug Delamanid, gene CYP3A4:\n",
      "Explanation 2: The main metabolic pathway of delamanid is primarily governed by the CYP3A4 enzyme. Variations in the CYP3A4 gene can affect the drug's pharmacokinetics due to changes in enzyme activity. This impacts its efficacy and safety, making it most probable that CYP3A4 holds the highest pharmacogenetic relevance for delamanid.\n",
      "Explanation 1: Delamanid is primarily metabolized by the CYP3A4 enzyme; hence variations in the genetic makeup of CYP3A4 considerably affect its pharmacokinetics in humans. Polymorphisms of CYP3A4 regulate the rate at which Delamanid is metabolized and thereby directly manipulate the drug's effectiveness and safety profile. Known drug interactions with CYP3A4 inducers or inhibitors affect Delamanid's metabolism, emphasizing the potential need to adjust Delamanid dosage based on CYP3A4 genetic variations and the presence of other CYP3A4-interacting drugs. Additionally, the same polymorphisms modify Delamanid's clearance levels, impacting drug concentration, distribution, and the overall outcome of the drug therapy.\n",
      "Cosine similarity: 0.8598\n",
      "→ Very similar content.\n",
      "Similarity: 0.8598\n",
      "\n",
      "Comparing explanations for drug ethambutol, gene GSTM1:\n",
      "Explanation 0: GSTM1 has a role in drug metabolism, detoxification, and consequent changes in plasma levels and elimination rate. Being a member of glutathione S-transferase genes that contribute to drug metabolism, including that of isoniazid, GSTM1 could potentially influence ethambutol's metabolism and toxicity.\n",
      "Explanation 1: GSTM1 plays a role in the metabolism and excretion of various drugs through glutathione conjugation. Given this function, it is likely that GSTM1 may contribute to the disposition and detoxification of ethambutol, potentially implicating it in ethambutol pharmacogenetics.\n",
      "Cosine similarity: 0.9205\n",
      "→ Very similar content.\n",
      "Similarity: 0.9205\n",
      "\n",
      "Comparing explanations for drug artemether, gene ABCB1:\n",
      "Explanation 0: The ABCB1 gene, encoding P-glycoprotein, could impact the pharmacokinetics, efficacy, and potential side effects of artemether. As an efflux transporter, ABCB1 affects drug distribution and excretion, and genetic variations can modulate its influence on this drug.\n",
      "Explanation 1: ABCB1, encoding the P-glycoprotein efflux transporter, plays a critical role in modulating the pharmacokinetics of artemether. This gene affects the absorption, distribution, and excretion of artemether, influencing the drug's bioavailability and the therapeutic outcomes. Thus, genetic variations in ABCB1 can have a significant pharmacogenetic impact on the effectiveness and tolerance of artemether.\n",
      "Cosine similarity: 0.9428\n",
      "→ Very similar content.\n",
      "Similarity: 0.9428\n",
      "\n",
      "Comparing explanations for drug levofloxacin, gene ABCG2:\n",
      "Explanation 1: The efflux transporter encoded by the ABCG2 gene significantly impacts the pharmacokinetics of various drugs by modifying absorption, distribution, and excretion, which in turn can affect their effectiveness and required dosages. Variants in ABCG2 can further alter these drug interactions, requiring adjustments in drug therapies to ensure optimal efficacy and safety. Given these properties, the potential pharmacogenetic relationship with levofloxacin is significant.\n",
      "Explanation 0: The ABCG2 gene, which codes for an efflux transporter protein, plays a significant role in determining the pharmacokinetics of various drugs by altering their absorption, distribution, and elimination. Genetic variants affecting ABCG2 can modify the efficacy and required dosages for drugs due to related changes in their bioavailability. In the context of levofloxacin, a likely pharmacogenetic interaction with ABCG2 can influence its concentration in target tissues and overall effectiveness.\n",
      "Cosine similarity: 0.9513\n",
      "→ Very similar content.\n",
      "Similarity: 0.9513\n",
      "\n",
      "Comparing explanations for drug Clofazimine, gene CYP2C9:\n",
      "Explanation 1: CYP2C9 is involved in drug metabolism and its polymorphisms affect the therapeutic effectiveness and risk side effects of multiple drugs. It is probable that genetic variations in this gene could influence the metabolism of clofazimine, possibly affecting its therapeutic effectiveness and safety. This potential impact on pharmacokinetics makes CYP2C9 a key player in the pharmacogenetic interaction with clofazimine.\n",
      "Explanation 0: CYP2C9, as a part of the cytochrome P450 enzyme family, is an enzyme potentially involved in the metabolism of cloves to clofazimine. Genetic variants of CYP2C9 may modulate the activity level of the enzyme, which could impact the pharmacokinetics of clofazimine, such as exposure level, efficacy, and risk of side effects.\n",
      "Cosine similarity: 0.8932\n",
      "→ Very similar content.\n",
      "Similarity: 0.8932\n",
      "\n",
      "Comparing explanations for drug streptomycin, gene SLC28A3:\n",
      "Explanation 0: SLC28A3, which encodes a concentrative nucleoside transporter, is involved in the uptake of nucleoside analogs into cells. While streptomycin isn't a nucleoside analog, this transporter's role in drug absorption and efficacy could potentially extend beyond its known substrates. Hence, genetic variations in SLC28A3 might impact the pharmacokinetic profile of streptomycin, possibly modulating streptomycin's effectiveness or toxicity.\n",
      "Explanation 1: The SLC28A3 gene, involved in the transport of nucleoside analogue drugs, significantly impacts their absorption, distribution, and elimination. Variations in this gene could potentially alter the therapeutic dosing of similar drugs used to treat infections.\n",
      "Cosine similarity: 0.8096\n",
      "→ Related but not identical.\n",
      "Similarity: 0.8096\n",
      "\n",
      "Comparing explanations for drug Bedaquiline, gene CYP3A5:\n",
      "Explanation 1: CYP3A5 is involved in the metabolism of many drugs and genetic variants in this gene can impact the metabolism rate, thereby influencing therapeutic outcomes and safety profiles of these drugs. This gene is a very probable candidate for pharmacogenetic interactions with Bedaquiline, owing to its role in the CYP3A family, the same family as CYP3A4, which is proven to interact with Bedaquiline. Potential differences in Bedaquiline metabolism due to CYP3A5 variance could affect its effectiveness and safety.\n",
      "Explanation 0: Beyond its relationship with CYP3A4, Bedaquiline may also interact with the CYP3A5 enzymatic pathway, considering their shared roles in drug metabolism. Variants in the CYP3A5 gene that alters enzyme activity can affect the metabolism rates of Bedaquiline, which in turn can influence its therapeutic outcomes and risk profiles.\n",
      "Cosine similarity: 0.8987\n",
      "→ Very similar content.\n",
      "Similarity: 0.8987\n",
      "\n",
      "Comparing explanations for drug artemether, gene CYP2D6:\n",
      "Explanation 1: While CYP2D6 has no known direct interaction with artemether, its critical role in the metabolism of many drugs implies a potential for indirect pharmacokinetic effects on artemether metabolism through shared pathways or competitive inhibition.\n",
      "Explanation 0: The CYP2D6 gene, while it does not directly metabolize artemether, is a key cytochrome P450 enzyme in the metabolism of many other drugs. Genetic variations in this gene could potentially lead to variability in the overall metabolic processing of drugs in the body and thus could indirectly affect the metabolism and efficacy of artemether.\n",
      "Cosine similarity: 0.8637\n",
      "→ Very similar content.\n",
      "Similarity: 0.8637\n",
      "\n",
      "Comparing explanations for drug isoniazid, gene NAT2:\n",
      "Explanation 0: NAT2 is a well-documented pharmacogenetic interaction for isoniazid. It encodes for an enzyme that is directly involved in isoniazid acetylation, a key step in the drug's metabolism. Variants in NAT2 cause variability in acetylation rates, categorizing individuals as rapid or slow acetylators, which directly affects the risk for isoniazid adverse effects such as hepatotoxicity and peripheral neuropathy.\n",
      "Explanation 2: NAT2 metabolizes isoniazid through acetylation, so its status directly influences the drug’s pharmacokinetics and side effects like hepatotoxicity and peripheral neuropathy. Differences in acetylator status, dictated by NAT2 variants, lead to variations in drug plasma levels, exposure duration, and adverse effects.\n",
      "Cosine similarity: 0.9213\n",
      "→ Very similar content.\n",
      "Similarity: 0.9213\n",
      "\n",
      "Comparing explanations for drug Terizidone, gene ABCB1:\n",
      "Explanation 1: Expressing the P-glycoprotein, the ABCB1 gene modulates the pharmacokinetics and efficacy of numerous drugs by influencing their absorption, distribution, and excretion. Terizidone's efficacy and safety seem to align with ABC transporter family function. Polymorphisms in the ABCB1 gene are likely to alter P-glycoprotein function, modulating terizidone's bioavailability, brain penetration, and elimination times, thereby impacting its therapeutic success and potential adverse effects.\n",
      "Explanation 0: Based on the provided information on Terizidone, ABCB1 might significantly influence the drug's pharmacokinetics. ABCB1, also known as P-glycoprotein, is fundamental in modulating the absorption, distribution, and excretion of multiple drugs, thereby affecting their bioavailability. For Terizidone, interaction with ABCB1 could alter its absorption and distribution, possibly influencing its therapeutic effectiveness and the required dosage.\n",
      "Cosine similarity: 0.9090\n",
      "→ Very similar content.\n",
      "Similarity: 0.9090\n",
      "\n",
      "Comparing explanations for drug streptomycin, gene SLC28A3:\n",
      "Explanation 1: The SLC28A3 gene, involved in the transport of nucleoside analogue drugs, significantly impacts their absorption, distribution, and elimination. Variations in this gene could potentially alter the therapeutic dosing of similar drugs used to treat infections.\n",
      "Explanation 2: The SLC28A3 gene is significant in the transport of nucleoside and nucleotide analog drugs, affecting their absorption, distribution, and elimination. Streptomycin, if structurally similar to these drugs, may be affected by SLC28A3.\n",
      "Cosine similarity: 0.9063\n",
      "→ Very similar content.\n",
      "Similarity: 0.9063\n",
      "\n",
      "Comparing explanations for drug clindamycin, gene CYP3A5:\n",
      "Explanation 0: CYP3A5, although not as significant as CYP3A4 in clindamycin's metabolism, also partakes in converting clindamycin into inactive metabolites. Thus, variations in this gene could have implications in the pharmacokinetics and efficacy of the drug. Therefore, CYP3A5 is ranked in third place due to its role in pharmaceutical metabolism.\n",
      "Explanation 2: Similar to CYP3A4, CYP3A5 plays a significant role in clindamycin metabolism. Polymorphisms in CYP3A5 are known to alter the metabolic rate of clindamycin, thereby modifying plasma drug concentrations and affecting its distribution and toxicity. These pharmacokinetic changes due to variations in CYP3A5 may potentially influence therapeutic outcomes and adverse effect profiles of clindamycin, making this gene highly relevant for its pharmacogenetic interactions.\n",
      "Cosine similarity: 0.9060\n",
      "→ Very similar content.\n",
      "Similarity: 0.9060\n",
      "\n",
      "Comparing explanations for drug ethambutol, gene CYP2C9:\n",
      "Explanation 1: CYP2C9 is another cytochrome P450 enzyme that significantly alters drug pharmacokinetics. Although the specific interaction between CYP2C9 and ethambutol is not well-documented, the gene might influence ethambutol’s pharmacokinetics, indicating CYP2C9's potential significance in ethambutol pharmacogenetics.\n",
      "Explanation 0: CYP2C9 genetic polymorphisms might influence the metabolism of ethambutol, affecting its therapeutic effectiveness. Given that CYP2C9 variations often lead to altered pharmacokinetic profiles for many drugs, it's likely that ethambutol, which has been suggested to have interactions with multiple CYP enzymes, may also exhibit such a pharmacokinetic interaction with this enzyme.\n",
      "Cosine similarity: 0.9094\n",
      "→ Very similar content.\n",
      "Similarity: 0.9094\n",
      "\n",
      "Comparing explanations for drug sulfadoxine, gene G6PD:\n",
      "Explanation 2: First and foremost, G6PD, which is responsible for the dehydrogenase action of glucose-6-phosphate, is of particular importance. This is the enzyme which is inhibited during the administration of sulfadoxine. Individuals with G6PD deficiency face the risk of hemolysis when administered the drug, due to the compounded inability of their red blood cells to produce sufficient reducing power to handle stress. This significant pharmacogenetic interplay of sulfadoxine's mechanism of action, the genetic background of the patient, and potential health outcomes marks G6PD as a key gene involved.\n",
      "Explanation 0: G6PD stands as the most likely drug-gene interaction for sulfadoxine due to direct pharmacodynamic considerations - G6PD deficiency can increase risks of hemolysis in patients treated with sulfadoxine. Given the drug's known interactions with G6PD, genetic screening is essential among users to avoid severe hemolytic reactions.\n",
      "Cosine similarity: 0.8602\n",
      "→ Very similar content.\n",
      "Similarity: 0.8602\n",
      "\n",
      "Comparing explanations for drug Capreomycin, gene ABCC2:\n",
      "Explanation 1: The ABCC2 gene encodes the MRP2 protein, an efflux transporter known to play a critical role in the pharmacokinetics of several drugs. Genetic variations in this gene, such as c.1249G>A and c.3972C>T, influence its function, thereby modifying the excretion and plasma concentrations of different drugs. As such, ABCC2 could potentially affect the effectiveness and toxicity of Capreomycin by modulating its transportation, absorption, distribution, and excretion within the body.\n",
      "Explanation 0: ABCC2, encoding the MRP2 protein, influences the function and pharmacokinetics of various drugs including antitubercular agents. Variations in ABCC2 can modify both drug excretion and plasma concentrations, leading to alterations in drug effectiveness and toxicity. Therefore, based on similar mechanisms, it is inferred that ABCC2 likely has a significant pharmacogenetic relationship with Capreomycin, influencing its pharmacokinetics and therapeutic outcomes.\n",
      "Cosine similarity: 0.9305\n",
      "→ Very similar content.\n",
      "Similarity: 0.9305\n",
      "\n",
      "Comparing explanations for drug artesunate, gene ABCB1:\n",
      "Explanation 0: The ABCB1 gene, encoding P-glycoprotein, modulates the pharmacokinetics of multiple drugs. It serves as a critical determinant of drug bioavailability and brain penetration. Also, based on the auxiliary information provided, direct pharmacokinetic interaction of artesunate with this transporter protein is well-established. Given the fundamental role of the ABCB1 gene in regulating drug excretion and distribution, it is a strong candidate for influencing the pharmacokinetics of artesunate.\n",
      "Explanation 2: The ABCB1 gene is already known to influence the pharmacokinetics of artesunate. The product of the ABCB1 gene, P-glycoprotein, modulates the absorption, distribution, and excretion of the drug, thereby affecting its bioavailability and even its ability to cross the blood-brain barrier. The lens of personalized medicine underscores the importance of considering potential variations in the ABCB1 gene that could modulate the interactions of artesunate with P-glycoprotein, possibly affecting the drug's efficacy and safety.\n",
      "Cosine similarity: 0.9458\n",
      "→ Very similar content.\n",
      "Similarity: 0.9458\n",
      "\n",
      "Comparing explanations for drug Bedaquiline, gene CYP3A4:\n",
      "Explanation 0: CYP3A4 gene has crucial pharmacogenetic implications for Bedaquiline. The drug's effectiveness and safety are significantly modulated by variations in the CYP3A4 gene, affecting its metabolism. Individuals with genetic variants enhancing or reducing CYP3A4 enzyme activity may experience either reduced efficacy or heightened risk of adverse effects like QT prolongation. This consequently necessitates consideration of dose adjustment or thorough monitoring, to balance the therapeutic benefits and risks.\n",
      "Explanation 2: CYP3A4 stands at rank one due to its direct involvement in the metabolism of Bedaquiline. The drug's effectiveness and safety are influenced by variations in the CYP3A4 gene, which affect Bedaquiline's pharmacokinetics, thereby calling for consideration of dose adjustments or thorough monitoring. Moreover, CYP3A4 affects the metabolism, effects, and toxicity of a wide array of drugs highlighting its central role in drug pharmacokinetics.\n",
      "Cosine similarity: 0.8934\n",
      "→ Very similar content.\n",
      "Similarity: 0.8934\n",
      "\n",
      "Comparing explanations for drug Capreomycin, gene ABCC3:\n",
      "Explanation 0: The ABCC3 gene significantly influences the pharmacokinetics and pharmacodynamics of various drugs, including antitubercular drugs. It primarily affects drug transport, and variants in ABCC3 can lead to altered excretion and hence the effectiveness and side effects of drugs including Capreomycin. Apart from pharmacokinetic influence, ABCC3 also has pharmacodynamic efficacy that may interact with Capreomycin, aligning with the reported auxiliary information.\n",
      "Explanation 1: ABCC3 plays a significant part in the pharmacokinetics and pharmacodynamics of several drugs, especially those used in chemotherapy. It may affect the transport and thus the excretion of Capreomycin, potentially influencing the drug's systemic and neurological effects.\n",
      "Cosine similarity: 0.8715\n",
      "→ Very similar content.\n",
      "Similarity: 0.8715\n",
      "\n",
      "Comparing explanations for drug Bedaquiline, gene UGT1A1:\n",
      "Explanation 1: UGT1A1 influences drug metabolism primarily through glucuronidation, affecting drug pharmacokinetics and pharmacodynamics. Variations in this gene have been linked to changes in the clearance of drugs, leading to different levels of drug toxicity. Potentially, such effects could alter the safety and efficacy profiles of drugs like Bedaquiline.\n",
      "Explanation 0: UGT1A1 is crucial for glucuronidation, a major phase II metabolic pathway. Variations in UGT1A1 can impact drug metabolism, affecting both pharmacokinetics and pharmacodynamics, and potentially contribute in tunnelling the metabolic shunts of Bedaquiline.\n",
      "Cosine similarity: 0.9003\n",
      "→ Very similar content.\n",
      "Similarity: 0.9003\n",
      "\n",
      "Comparing explanations for drug artesunate, gene ABCB1:\n",
      "Explanation 2: The ABCB1 gene is already known to influence the pharmacokinetics of artesunate. The product of the ABCB1 gene, P-glycoprotein, modulates the absorption, distribution, and excretion of the drug, thereby affecting its bioavailability and even its ability to cross the blood-brain barrier. The lens of personalized medicine underscores the importance of considering potential variations in the ABCB1 gene that could modulate the interactions of artesunate with P-glycoprotein, possibly affecting the drug's efficacy and safety.\n",
      "Explanation 1: ABCB1, encoding P-glycoprotein, has been linked to artesunate transport. Its variants affect drug absorption, distribution, excretion, and bioavailability. It would be reasonable to infer a pharmacogenetic relationship between ABCB1 and artesunate, ranking it favorably due to these established associations.\n",
      "Cosine similarity: 0.8950\n",
      "→ Very similar content.\n",
      "Similarity: 0.8950\n",
      "\n",
      "Comparing explanations for drug primaquine, gene CYP1B1:\n",
      "Explanation 1: Similar to CYP1A1, CYP1B1 has a significant effect on primaquine metabolism. Consequently, any genetic variability of this gene would impact the drug’s efficacy and toxicity.\n",
      "Explanation 0: CYP1B1's involvement in drug metabolism, its interaction with various drugs, and its pharmacokinetic and pharmacodynamic attributes suggest that it may reasonably have a pharmacogenetically significant interaction with primaquine. The enzyme has been shown to affect the efficacy and toxicity of various drugs, and it is plausible that analogous effects may occur with primaquine.\n",
      "Cosine similarity: 0.8763\n",
      "→ Very similar content.\n",
      "Similarity: 0.8763\n",
      "\n",
      "Comparing explanations for drug ethionamide, gene NAT2:\n",
      "Explanation 2: NAT2 encodes an enzyme that is crucial for drug metabolism via N-acetylation, directly influencing pharmacokinetics and toxicity. Polymorphisms in NAT2 affect the metabolism of a range of drugs, leading to individual differences in acetylator status (rapid, intermediate, slow), which impact drug plasma levels, exposure duration, and risk of adverse effects. As ethionamide's efficacy can vary due to differences in hepatic metabolism, the role of NAT2 in drug metabolisation makes it a high potential pharmacogenetic relationship with ethionamide.\n",
      "Explanation 1: NAT2 is a crucial enzyme for the metabolism of various drugs, including anti-tuberculosis drugs. Ethionamide, an analogous drug to isoniazid, also used against tuberculosis, might be influenced by NAT2 activity. Increased or decreased NAT2 activity due to genetic variations could affect the metabolism and efficacy of ethionamide, influencing its therapeutic outcome, leading to differences in acetylator status (rapid, intermediate, slow) among individuals. This status impacts maximum drug plasma levels, exposure duration, and risk of adverse effects such as increased toxicity.\n",
      "Cosine similarity: 0.8751\n",
      "→ Very similar content.\n",
      "Similarity: 0.8751\n",
      "\n",
      "Comparing explanations for drug P-aminosalicylic acid, gene CYP2C8:\n",
      "Explanation 1: The CYP2C8 gene is known to influence the metabolism of various medications, hence, it is possible that it could interact with p-aminosalicylic acid. Variations in CYP2C8 can lead to alterations in drug metabolism, exposure, and toxicity which may affect p-aminosalicylic acid's therapeutic profiles, although such interaction requires further validation.\n",
      "Explanation 0: CYP2C8 is known for playing a critical role in the metabolism of drugs like paclitaxel, pioglitazone, repaglinide, and amodiaquine. Genetic variations that influence drug metabolism and exposure directly impact the efficacy and toxicity profiles of these drugs, suggesting the potential utility of CYP2C8 genetic testing in optimizing drug dosing and reducing toxicity risks.\n",
      "Cosine similarity: 0.6746\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6746\n",
      "\n",
      "Comparing explanations for drug mefloquine, gene CYP2C9:\n",
      "Explanation 0: CYP2C9 gene polymorphisms can influence metabolism of numerous drugs, thereby affecting their therapeutic effectiveness and risk of adverse effects. Drugs such as anticoagulants and antiepileptics require dose customization based on CYP2C9 genetic variants to optimize treatment outcomes and minimize complications. Considering these known pharmacogenetic interactions, the CYP2C9 gene may be plausibly associated with modifications to the pharmacokinetics of mefloquine.\n",
      "Explanation 1: CYP2C9 gene polymorphisms influence the metabolism of various drugs, affecting their therapeutic effectiveness and risk of side effects. Although not directly linked to mefloquine, the drug might still exhibit altered pharmacokinetic profiles and thereby efficacy or safety due to its potential metabolism by CYP2C9, aiding in personalized medicine efforts.\n",
      "Cosine similarity: 0.9313\n",
      "→ Very similar content.\n",
      "Similarity: 0.9313\n",
      "\n",
      "Comparing explanations for drug streptomycin, gene SLC28A3:\n",
      "Explanation 0: SLC28A3, which encodes a concentrative nucleoside transporter, is involved in the uptake of nucleoside analogs into cells. While streptomycin isn't a nucleoside analog, this transporter's role in drug absorption and efficacy could potentially extend beyond its known substrates. Hence, genetic variations in SLC28A3 might impact the pharmacokinetic profile of streptomycin, possibly modulating streptomycin's effectiveness or toxicity.\n",
      "Explanation 2: The SLC28A3 gene is significant in the transport of nucleoside and nucleotide analog drugs, affecting their absorption, distribution, and elimination. Streptomycin, if structurally similar to these drugs, may be affected by SLC28A3.\n",
      "Cosine similarity: 0.8882\n",
      "→ Very similar content.\n",
      "Similarity: 0.8882\n",
      "\n",
      "Comparing explanations for drug artesunate, gene CYP3A5:\n",
      "Explanation 2: Similar to CYP2B6, CYP3A5 is known to be part of the metabolism of several drugs. CYP3A5 metabolizes drugs such as tacrolimus, imatinib, statins, apixaban, vincristine, ondansetron, atazanavir, and fentanyl. Given the proximity and cooperation of the CYP3A enzymes, pharmacogenetic variations in the CYP3A5 gene could also potentially affect the metabolism of artesunate.\n",
      "Explanation 0: CYP3A5 interacts with an array of drugs, influencing their metabolic pathways and in turn, their therapeutic outcomes and risk profiles. Even though there is no direct evidence of a pharmacokinetic interaction with artesunate, the potential interaction inferred due to the crucial role of this gene in drug metabolism earns it a place in this ranking.\n",
      "Cosine similarity: 0.8006\n",
      "→ Related but not identical.\n",
      "Similarity: 0.8006\n",
      "\n",
      "Comparing explanations for drug Terizidone, gene ABCB1:\n",
      "Explanation 0: Based on the provided information on Terizidone, ABCB1 might significantly influence the drug's pharmacokinetics. ABCB1, also known as P-glycoprotein, is fundamental in modulating the absorption, distribution, and excretion of multiple drugs, thereby affecting their bioavailability. For Terizidone, interaction with ABCB1 could alter its absorption and distribution, possibly influencing its therapeutic effectiveness and the required dosage.\n",
      "Explanation 1: Expressing the P-glycoprotein, the ABCB1 gene modulates the pharmacokinetics and efficacy of numerous drugs by influencing their absorption, distribution, and excretion. Terizidone's efficacy and safety seem to align with ABC transporter family function. Polymorphisms in the ABCB1 gene are likely to alter P-glycoprotein function, modulating terizidone's bioavailability, brain penetration, and elimination times, thereby impacting its therapeutic success and potential adverse effects.\n",
      "Cosine similarity: 0.9090\n",
      "→ Very similar content.\n",
      "Similarity: 0.9090\n",
      "\n",
      "Comparing explanations for drug streptomycin, gene ABCG2:\n",
      "Explanation 2: The ABCG2 gene, notably, influences the pharmacokinetics of many drugs by altering their absorption, distribution, and excretion. Changes in ABCG2 gene can further modify these drug interactions, potentially impacting streptomycin's absorption, distribution, and excretion.\n",
      "Explanation 0: ABCG2 is another key transporter gene, encoding for an efflux transporter, BCRP, that can modulate the absorption, distribution, and excretion of numerous drugs. BCRP has been shown to interact with various substrates including chemotherapeutic drugs and antibiotics. Being an aminoglycoside, streptomycin may interact with ABCG2 in a similar manner, affecting the drug's pharmacokinetics and pharmacodynamics that could impact its therapeutic effectiveness and safety profile.\n",
      "Cosine similarity: 0.8709\n",
      "→ Very similar content.\n",
      "Similarity: 0.8709\n",
      "\n",
      "Comparing explanations for drug levofloxacin, gene ABCG2:\n",
      "Explanation 1: The efflux transporter encoded by the ABCG2 gene significantly impacts the pharmacokinetics of various drugs by modifying absorption, distribution, and excretion, which in turn can affect their effectiveness and required dosages. Variants in ABCG2 can further alter these drug interactions, requiring adjustments in drug therapies to ensure optimal efficacy and safety. Given these properties, the potential pharmacogenetic relationship with levofloxacin is significant.\n",
      "Explanation 0: The ABCG2 gene, which codes for an efflux transporter protein, plays a significant role in determining the pharmacokinetics of various drugs by altering their absorption, distribution, and elimination. Genetic variants affecting ABCG2 can modify the efficacy and required dosages for drugs due to related changes in their bioavailability. In the context of levofloxacin, a likely pharmacogenetic interaction with ABCG2 can influence its concentration in target tissues and overall effectiveness.\n",
      "Cosine similarity: 0.9513\n",
      "→ Very similar content.\n",
      "Similarity: 0.9513\n",
      "\n",
      "Comparing explanations for drug artemether, gene CYP2D6:\n",
      "Explanation 1: While CYP2D6 has no known direct interaction with artemether, its critical role in the metabolism of many drugs implies a potential for indirect pharmacokinetic effects on artemether metabolism through shared pathways or competitive inhibition.\n",
      "Explanation 0: The CYP2D6 gene, while it does not directly metabolize artemether, is a key cytochrome P450 enzyme in the metabolism of many other drugs. Genetic variations in this gene could potentially lead to variability in the overall metabolic processing of drugs in the body and thus could indirectly affect the metabolism and efficacy of artemether.\n",
      "Cosine similarity: 0.8638\n",
      "→ Very similar content.\n",
      "Similarity: 0.8638\n",
      "\n",
      "Comparing explanations for drug Bedaquiline, gene CYP2C19:\n",
      "Explanation 1: CYP2C19 plays a significant role in the metabolism of a range of drugs, with variations in the gene influencing drug activation and clearance. Although not yet established, a possible interaction between CYP2C19 and Bedaquiline may exist, given that several other cytochrome P450 enzymes interact with the drug. Variations in CYP2C19 could potentially affect the therapeutic outcomes of Bedaquiline by impacting its metabolism.\n",
      "Explanation 0: CYP2C19 enzymatic pathway significantly influences the metabolism of various clinically relevant drugs. Therefore, it could potentially interact with pharmacokinetic processes related to Bedaquiline. Understanding its influence may provide valuable insights into optimizing the drug's therapeutic efficacy while minimizing side effects.\n",
      "Cosine similarity: 0.9032\n",
      "→ Very similar content.\n",
      "Similarity: 0.9032\n",
      "\n",
      "Comparing explanations for drug P-aminosalicylic acid, gene NAT2:\n",
      "Explanation 0: NAT2 is an enzyme known to play a substantial part in the metabolism of various drugs, substantially affecting their pharmacokinetics and toxicity levels. Its variants have previously been noted to modify the metabolism of drugs such as isoniazid, hydralazine, procainamide, sulfamethoxazole, and pyrazinamide. This results in individuals presenting with differing acetylator status, namely rapid, intermediate, or slow, which impacts drug plasma levels, exposure duration, and risk of adverse effects - including increased toxicity and drug-induced lupus.\n",
      "Explanation 2: NAT2 acetylates P-aminosalicylic acid in the human liver. Acetylation of the drug leads to urinary excretion. NAT2 fast metabolizers excrete the drug more rapidly and therefore need higher doses. On the other hand, NAT2 slow metabolizers have elevated plasma levels and may experience increased toxicity. Therefore, NAT2 pharmacogenetic testing can personalize the treatment with P-aminosalicylic acid, lowering the risk of side effects and ensuring the expected therapeutic effect.\n",
      "Cosine similarity: 0.7737\n",
      "→ Related but not identical.\n",
      "Similarity: 0.7737\n",
      "\n",
      "Comparing explanations for drug lumefantrine, gene ABCC2:\n",
      "Explanation 0: ABCC2 encodes the MRP2 protein, which plays a significant role in drug excretion, affecting the pharmacokinetics of various drugs. Variations in this gene can alter plasma concentrations of drugs, leading to changes in their effectiveness and toxicity. Notably, lumefantrine is among the drugs influenced by ABCC2, making this gene an important factor to consider in personalized treatment planning for malaria. Furthermore, considering the broader role of MRP2 in efflux transport mechanisms, ABCC2 could indirectly modify interaction outcomes with additional drugs utilized alongside lumefantrine.\n",
      "Explanation 2: The ATP-binding cassette transporter ABCC2, also known as MRP2, is mainly expressed in the liver and kidney. It significantly contributes to the biliary and renal elimination of lumefantrine and its metabolites. Thus, variants in the ABCC2 gene that affect the function of this transporter can lead to altered lumefantrine levels, affecting its efficacy and safety.\n",
      "Cosine similarity: 0.8584\n",
      "→ Very similar content.\n",
      "Similarity: 0.8584\n",
      "\n",
      "Comparing explanations for drug Rifapentine, gene CYP3A5:\n",
      "Explanation 1: Similar to CYP3A4, CYP3A5 also plays a crucial role in the metabolism of several drugs. Genetic variations in this gene are known to affect metabolism rates and ultimately influence the therapeutic outcomes and risk profiles of numerous drugs.\n",
      "Explanation 0: CYP3A5 plays a role in the metabolism of several drugs, including Rifapentine. Variations in CYP3A5 function can contribute to interindividual differences in Rifapentine's pharmacokinetics like rate of metabolism, drug exposure, and drug clearance. This interaction can influence the therapeutic outcomes and risk profiles of Rifapentine.\n",
      "Cosine similarity: 0.7596\n",
      "→ Related but not identical.\n",
      "Similarity: 0.7596\n",
      "\n",
      "Comparing explanations for drug Bedaquiline, gene ABCB1:\n",
      "Explanation 0: ABCB1 encodes P-glycoprotein which is vital in modulating the pharmacokinetics and efficacy of Bedaquiline. It acts as an efflux transporter, influencing the absorption, distribution, and elimination of the drug. Importantly, ABCB1 can impact the bioavailability and cellular concentration of drugs. Thus, variations in the ABCB1 gene that modify transporter function may affect drug efficacy and toxicity.\n",
      "Explanation 1: ABCB1 encodes the drug efflux pump P-glycoprotein that impacts the pharmacokinetics and overall efficacy of multiple drugs. It plays a decisive role in the absorption, distribution, and elimination of various drugs. The variability in the function of P-glycoprotein due to changes in ABCB1 can lead to alterations in drug efficacy, potentially necessitating dosage adjustments for optimum therapeutic outcomes. For Bedaquiline, being a substrate of P-glycoprotein, ABCB1 is likely to be a significant player in its pharmacogenetics.\n"
     ]
    }
   ],
   "source": [
    "explanations = [df[\"explanation_0\"].tolist(), \n",
    "                df[\"explanation_1\"].tolist(), \n",
    "                df[\"explanation_2\"].tolist()]\n",
    "\n",
    "row_idxs = [i for i in range(df.shape[0])]\n",
    "col_idxs = [i for i in range(3)]\n",
    "\n",
    "similarities = []\n",
    "for _ in range(10000):\n",
    "    row_idx = np.random.choice(row_idxs)\n",
    "    col_idx_0 = np.random.choice(col_idxs)\n",
    "    col_idx_1 = np.random.choice(col_idxs)\n",
    "    if col_idx_0 == col_idx_1:\n",
    "        continue\n",
    "    p1 = explanations[col_idx_0][row_idx]\n",
    "    p2 = explanations[col_idx_1][row_idx]\n",
    "    if p1 is None or p2 is None:\n",
    "        continue\n",
    "    print(f\"Comparing explanations for drug {df['drug'][row_idx]}, gene {df['gene'][row_idx]}:\")\n",
    "    print(f\"Explanation {col_idx_0}: {p1}\")\n",
    "    print(f\"Explanation {col_idx_1}: {p2}\")\n",
    "    similarity = paragraph_similarity(p1, p2)\n",
    "    similarities += [similarity]\n",
    "    if len(similarities) > 1000:\n",
    "        break \n",
    "    with open(\"assets/similarities.csv\", \"a\") as f:\n",
    "        f.write(f\"{df['drug'][row_idx]},{df['gene'][row_idx]},{col_idx_0},{col_idx_1},{similarity}\\n\")\n",
    "    print(f\"Similarity: {similarity:.4f}\\n\")\n",
    "\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Cosine similarity: 0.6656\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6656\n",
      "\n",
      "Cosine similarity: 0.4915\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4915\n",
      "\n",
      "Cosine similarity: 0.4205\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4205\n",
      "\n",
      "Cosine similarity: 0.5290\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5290\n",
      "\n",
      "Cosine similarity: 0.4662\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4662\n",
      "\n",
      "Cosine similarity: 0.4122\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4122\n",
      "\n",
      "Cosine similarity: 0.3642\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.3642\n",
      "\n",
      "Cosine similarity: 0.5999\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5999\n",
      "\n",
      "Cosine similarity: 0.4511\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4511\n",
      "\n",
      "Cosine similarity: 0.4686\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4686\n",
      "\n",
      "Cosine similarity: 0.6628\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6628\n",
      "\n",
      "Cosine similarity: 0.6645\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6645\n",
      "\n",
      "Cosine similarity: 0.4118\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4118\n",
      "\n",
      "Cosine similarity: 0.4434\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4434\n",
      "\n",
      "Cosine similarity: 0.7213\n",
      "→ Related but not identical.\n",
      "Similarity: 0.7213\n",
      "\n",
      "Cosine similarity: 0.6702\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6702\n",
      "\n",
      "Cosine similarity: 0.5089\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5089\n",
      "\n",
      "Cosine similarity: 0.5431\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5431\n",
      "\n",
      "Cosine similarity: 0.4622\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4622\n",
      "\n",
      "Cosine similarity: 0.4133\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4133\n",
      "\n",
      "Cosine similarity: 0.5869\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5869\n",
      "\n",
      "Cosine similarity: 0.4673\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4673\n",
      "\n",
      "Cosine similarity: 0.5475\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5475\n",
      "\n",
      "Cosine similarity: 0.5114\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5114\n",
      "\n",
      "Cosine similarity: 0.6504\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6504\n",
      "\n",
      "Cosine similarity: 0.5029\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5029\n",
      "\n",
      "Cosine similarity: 0.5606\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5606\n",
      "\n",
      "Cosine similarity: 0.4539\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4539\n",
      "\n",
      "Cosine similarity: 0.6262\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6262\n",
      "\n",
      "Cosine similarity: 0.5696\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5696\n",
      "\n",
      "Cosine similarity: 0.5388\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5388\n",
      "\n",
      "Cosine similarity: 0.6878\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6878\n",
      "\n",
      "Cosine similarity: 0.4425\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4425\n",
      "\n",
      "Cosine similarity: 0.5236\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5236\n",
      "\n",
      "Cosine similarity: 0.6804\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6804\n",
      "\n",
      "Cosine similarity: 0.4034\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4034\n",
      "\n",
      "Cosine similarity: 0.5952\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5952\n",
      "\n",
      "Cosine similarity: 0.5369\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5369\n",
      "\n",
      "Cosine similarity: 0.4658\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4658\n",
      "\n",
      "Cosine similarity: 0.4448\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4448\n",
      "\n",
      "Cosine similarity: 0.6966\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6966\n",
      "\n",
      "Cosine similarity: 0.4541\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4541\n",
      "\n",
      "Cosine similarity: 0.4101\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4101\n",
      "\n",
      "Cosine similarity: 0.4380\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4380\n",
      "\n",
      "Cosine similarity: 0.6237\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6237\n",
      "\n",
      "Cosine similarity: 0.4671\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4671\n",
      "\n",
      "Cosine similarity: 0.7225\n",
      "→ Related but not identical.\n",
      "Similarity: 0.7225\n",
      "\n",
      "Cosine similarity: 0.7418\n",
      "→ Related but not identical.\n",
      "Similarity: 0.7418\n",
      "\n",
      "Cosine similarity: 0.3526\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.3526\n",
      "\n",
      "Cosine similarity: 0.4538\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4538\n",
      "\n",
      "Cosine similarity: 0.4770\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4770\n",
      "\n",
      "Cosine similarity: 0.7534\n",
      "→ Related but not identical.\n",
      "Similarity: 0.7534\n",
      "\n",
      "Cosine similarity: 0.4432\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4432\n",
      "\n",
      "Cosine similarity: 0.4077\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4077\n",
      "\n",
      "Cosine similarity: 0.3833\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.3833\n",
      "\n",
      "Cosine similarity: 0.3910\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.3910\n",
      "\n",
      "Cosine similarity: 0.6057\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6057\n",
      "\n",
      "Cosine similarity: 0.4773\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4773\n",
      "\n",
      "Cosine similarity: 0.4949\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4949\n",
      "\n",
      "Cosine similarity: 0.5250\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5250\n",
      "\n",
      "Cosine similarity: 0.5320\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5320\n",
      "\n",
      "Cosine similarity: 0.5822\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5822\n",
      "\n",
      "Cosine similarity: 0.6303\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6303\n",
      "\n",
      "Cosine similarity: 0.4189\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4189\n",
      "\n",
      "Cosine similarity: 0.6113\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6113\n",
      "\n",
      "Cosine similarity: 0.4543\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4543\n",
      "\n",
      "Cosine similarity: 0.7247\n",
      "→ Related but not identical.\n",
      "Similarity: 0.7247\n",
      "\n",
      "Cosine similarity: 0.6179\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6179\n",
      "\n",
      "Cosine similarity: 0.5045\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5045\n",
      "\n",
      "Cosine similarity: 0.7842\n",
      "→ Related but not identical.\n",
      "Similarity: 0.7842\n",
      "\n",
      "Cosine similarity: 0.4797\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4797\n",
      "\n",
      "Cosine similarity: 0.4503\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4503\n",
      "\n",
      "Cosine similarity: 0.4894\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4894\n",
      "\n",
      "Cosine similarity: 0.4648\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4648\n",
      "\n",
      "Cosine similarity: 0.4254\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4254\n",
      "\n",
      "Cosine similarity: 0.5454\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5454\n",
      "\n",
      "Cosine similarity: 0.4828\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4828\n",
      "\n",
      "Cosine similarity: 0.4911\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4911\n",
      "\n",
      "Cosine similarity: 0.4887\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4887\n",
      "\n",
      "Cosine similarity: 0.5968\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5968\n",
      "\n",
      "Cosine similarity: 0.6746\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6746\n",
      "\n",
      "Cosine similarity: 0.5274\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5274\n",
      "\n",
      "Cosine similarity: 0.4590\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4590\n",
      "\n",
      "Cosine similarity: 0.7331\n",
      "→ Related but not identical.\n",
      "Similarity: 0.7331\n",
      "\n",
      "Cosine similarity: 0.4704\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4704\n",
      "\n",
      "Cosine similarity: 0.8551\n",
      "→ Very similar content.\n",
      "Similarity: 0.8551\n",
      "\n",
      "Cosine similarity: 0.5690\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.5690\n",
      "\n",
      "Cosine similarity: 0.4777\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4777\n",
      "\n",
      "Cosine similarity: 0.4420\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4420\n",
      "\n",
      "Cosine similarity: 0.6620\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6620\n",
      "\n",
      "Cosine similarity: 0.4760\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4760\n",
      "\n",
      "Cosine similarity: 0.6541\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6541\n",
      "\n",
      "Cosine similarity: 0.4840\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4840\n",
      "\n",
      "Cosine similarity: 0.4441\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4441\n",
      "\n",
      "Cosine similarity: 0.4704\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4704\n",
      "\n",
      "Cosine similarity: 0.6317\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6317\n",
      "\n",
      "Cosine similarity: 0.4912\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4912\n",
      "\n",
      "Cosine similarity: 0.4442\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4442\n",
      "\n",
      "Cosine similarity: 0.6350\n",
      "→ Related but not identical.\n",
      "Similarity: 0.6350\n",
      "\n",
      "Cosine similarity: 0.4427\n",
      "→ Possibly unrelated.\n",
      "Similarity: 0.4427\n",
      "\n",
      "Cosine similarity: 0.5839\n",
      "→ Possibly unrelated.\n"
     ]
    }
   ],
   "source": [
    "rand_similarities = []\n",
    "for _ in range(10000):\n",
    "    row_idx_0 = np.random.choice(row_idxs)\n",
    "    row_idx_1 = np.random.choice(row_idxs)\n",
    "    if row_idx_0 == row_idx_1:\n",
    "        continue\n",
    "    col_idx_0 = np.random.choice(col_idxs)\n",
    "    col_idx_1 = np.random.choice(col_idxs)\n",
    "    if col_idx_0 == col_idx_1:\n",
    "        continue\n",
    "    p1 = explanations[col_idx_0][row_idx_0]\n",
    "    p2 = explanations[col_idx_1][row_idx_1]\n",
    "    if p1 is None or p2 is None:\n",
    "        continue\n",
    "    similarity = paragraph_similarity(p1, p2)\n",
    "    rand_similarities += [similarity]\n",
    "    if len(rand_similarities) > 1000:\n",
    "        break \n",
    "    with open(\"assets/random_similarities.csv\", \"a\") as f:\n",
    "        f.write(f\"{similarity}\\n\")\n",
    "    print(f\"Similarity: {similarity:.4f}\\n\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "gardp",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
